|
Macrogenics Inc (NASDAQ: MGNX) |
|
Macrogenics Inc
MGNX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Macrogenics Inc growth rates, revenue grew
by 964.81 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2618
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.73 %
Macrogenics Inc 's net income grew by 220.78 % in III. Quarter 2024 year on year, above company average,
• More on MGNX's Growth
|
|
Macrogenics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 2.39 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.52.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.18.
• More on MGNX's Valuation
|
|
|
|
|
Macrogenics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 2.39 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.52.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.18.
Macrogenics Inc Price to Book Ratio is at 1.79 lower than Industry Avg. of 79.43. and higher than S&P 500 Avg. of 0.01
• More on MGNX's Valuation
|
|
MGNX's Profitability Comparisons
|
Macrogenics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 48.95 %.
Macrogenics Inc net profit margin of 50.86 % is currently ranking no. 7 in Major Pharmaceutical Preparations industry, ranking no. 12 in Healthcare sector and number 126 in S&P 500.
Profitability by Segment |
Total |
50.86 % |
|
|
Macrogenics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 48.95 %.
Macrogenics Inc net profit margin of 50.86 % is currently ranking no. 7 in Major Pharmaceutical Preparations industry, ranking no. 12 in Healthcare sector and number 126 in S&P 500.
• More on MGNX's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com